Base to Base biotech podcast 14: How to build reputation, and treating spastic paraplegia 47

This week, we have conversations with Peter Nolan, CEO of BlackFinBio, and Kim Kraemer, CEO and founder of Waterhouse Brands.

Interview times:

01:57 BlackFinBio

19:36 Waterhouse Brands

BlackFinBio

BlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases.

Its pipeline comprises BFB-101, a clinical stage AP4B1 replacement adeno-associated virus (AAV) gene therapy for spastic paraplegia 47 – an ultra-rare genetic neurological disease for which no treatment currently exists.

BFB-201 is a preclinical stage gene therapy to treat several rare dopamine deficiency disorders.

The U. ...